First National Bank of Hutchinson Purchases Shares of 1,882 Johnson & Johnson (NYSE:JNJ)

First National Bank of Hutchinson acquired a new position in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, HoldingsChannel reports. The firm acquired 1,882 shares of the company’s stock, valued at approximately $272,000.

A number of other institutional investors have also modified their holdings of JNJ. Next Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 5.4% during the 4th quarter. Next Capital Management LLC now owns 3,483 shares of the company’s stock valued at $504,000 after acquiring an additional 180 shares in the last quarter. L.K. Benson & Company P.C. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $219,000. First Financial Bankshares Inc boosted its position in shares of Johnson & Johnson by 2.4% in the fourth quarter. First Financial Bankshares Inc now owns 645,357 shares of the company’s stock worth $93,332,000 after buying an additional 15,291 shares during the period. Generali Investments Management Co LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $3,354,000. Finally, GM Advisory Group LLC raised its holdings in shares of Johnson & Johnson by 10.3% during the 4th quarter. GM Advisory Group LLC now owns 13,392 shares of the company’s stock valued at $1,937,000 after buying an additional 1,249 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Trading Down 0.8 %

Shares of NYSE:JNJ opened at $163.01 on Thursday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $392.83 billion, a PE ratio of 24.51, a P/E/G ratio of 2.56 and a beta of 0.47. The company’s 50-day moving average price is $156.15 and its 200 day moving average price is $156.30.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.